The highly selective, oral B-cell lymphoma 2 (BCL-2) inhibitor venetoclax has been shown to be very effective for the treatment of chronic lymphocytic leukemia (CLL) [1]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.